

Autoimmune Disease: A Modern Epidemic?

Molecular Mimicry, the Hygiene Hypothesis, Stealth Infections, and Other Examples of Disconnect Between Medical Research and the Practice of Clinical Medicine


By David M. Brady, ND, DC, CCN, DACBN

The genesis of this article is as a follow-up to a presentation delivered at the 2011 American Association of Naturopathic Physicians (AANP) annual convention on the topic of autoimmune disease, which resulted in a substantial amount of inquiry and requests for further exploration of the topics presented. There is simply no doubt that the incidence of autoimmune disorders has been rising sharply over the past several decades in the Western industrialized countries, particularly the US (Figure 1).¹ A broad array of disorders considered immune-dysregulatory and autoimmune in nature, encompassing both those classically categorized as Th1- and Th2-dominant, are included in this phenomenon. The question is, why has there been such a sharp rise in the incidence of these disorders? The answers may very well be found in the current medical research, but you would probably never know it by visiting a doctor. This may be because this situation serves as an example of the giant chasm that often exists between Western medical research, which is often outstanding, and the practice of clinical medicine, which often leaves quite a bit to be desired when it comes to the management of chronic disorders with high morbidity but low mortality.

The typical allopathic clinical approach to autoimmune disorders focuses on the management of symptoms with various anti-inflammatory medications and often the use of chemotherapeutics, and very potent

immunosuppressive agents with nasty potential side effects such as leukemia and lymphoma.² While these approaches admittedly can provide substantial symptomatic relief to the patient, they do not get to the cause of these conditions, and some research suggests that these approaches may result in a furthering of the pathological process.

Figure 1: Rising Incidence of Autoimmune Disorders



From: Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. *N Engl J Med.* Sep 2002;347(12):911-920.

However, modern research into autoimmune phenomena suggests that radically different approaches may be required to reverse the above-cited trends, including a strong emphasis on very early detection with predictive autoantibodies, a

focus on optimizing gastrointestinal mucosal immune function and the microbiome, eradication of infectious agent triggers with antimicrobial therapy, and even the seemingly bizarre use of parasitic agents therapeutically. Some of these concepts have a long history in naturopathic and functional models of medicine, but now are emerging as hot areas of emphasis in mainstream medical research journals and investigative communities in immunology.

Molecular Mimicry

The concept of molecular mimicry is a simple one, and it is an area attracting considerable research related to the genesis of autoimmune disorders. Simply stated, environmental exposure to specific antigens (including dietary peptides and those expressed by microbes) can in genetically susceptible individuals induce cross-reactions with structurally similar amino acid motifs associated with specific host tissues. There are now multitudes of associations that have been firmly established between immune incompatibility with specific dietary-derived antigens, as well as the overgrowth of certain opportunistic and pathogenic gastrointestinal bacteria, and the presence of specific autoimmune disorders (Table 1).³ While some of these associations have been known for quite some time, mechanisms of causality are rapidly being established in the research. However, patients suffering from disorders such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), and autoimmune thyroiditis (i.e., Hashimoto's or Graves' disease) who visit a rheumatologist or endocrinologist do not routinely have stool analysis of their GI microbiota or food sensitivity testing performed. This is ironic, particularly in the case of opportunistic microbial overgrowth in the gut, as the conventional medical paradigm typically assumes an infectious cause, doesn't it? Perhaps this is just another example of resistance to significant change in clinical approach within medicine, even in the face of compelling evidence

to do so, as it would then require a least a passive admission that something so seemingly simple was missed for so long.

Table 1: Selected Associations of Microbial Overgrowth and Autoimmune Disorders

Microbe Species	Disorder
<i>Klebsiella</i>	Ankylosing spondylitis
<i>Citrobacter, Klebsiella, Proteus</i>	Rheumatoid arthritis
<i>Porphyromonas Yersinia</i>	Graves' disease & Hashimoto's disease
<i>S. Pyogenes</i>	Rheumatic fever
<i>Campylobacter</i>	Guillain-Barré syndrome
<i>Chlamydia</i>	Multiple sclerosis
<i>E. coli, Proteus</i>	Autoimmunity in general

Pishak et al. have demonstrated that the mucous membranes of healthy people are colonized by Bifidobacteria, Lactobacilli, Bacteroides, Escherichia, and Enterococci, as contrasted with the mucous membranes in RA subjects, which are mainly colonized by aerobic opportunistic conventionally pathogenic enterobacteria (i.e., enteropathogenic Escherichia, Citrobacter, Enterobacter, Klebsiella, etc.), Staphylococci, Enterococci, and other anaerobic bacteria (Bacteroides, Peptococci, Peptostreptococci, etc.).⁴ They have also reported the observed phenomenon that as RA exacerbates and then enters remission, a common occurrence across the spectrum of autoimmune disorders, the composition of the subject's GI microbiota correspondingly also changes between the aberrant pattern detailed above and the one typical of normal subjects. The data of Tiwana et al. suggest an increased immune response to Klebsiella in patients with AS, ulcerative colitis (UC), and Crohn's disease (CD) and to Proteus in patients with RA.⁵

Alan Ebringer and his group in the UK have established over the course of many years that a substantial percentage of patients diagnosed with RA have chronic stealth infection with Proteus

mirabilis in the upper urinary tract.⁶ His group has also established the specific amino acid motifs of cross-reaction between the Proteus hemolysin and the RA-associated HLA-DR molecules, as well as

those between the Proteus urease enzyme and hyaline cartilage, containing type XI collagen, the type only found in the small joints affected in RA. His successful treatment protocol includes antibiotic therapy, such as ciprofloxacin (sometimes in combination with NSAIDs, DMARDs, and immunosuppressive agents as needed), with the added use of natural blocking agents such as cranberry juice, vitamin C for urine acidification, and plenty of fluids.⁷

Oral bacterial infection with Porphyromonas gingivalis, the primary cause of periodontal disease, may also play a role in peptide citrullination, theorized to be involved in the loss of self-tolerance and development of autoimmunity in RA, according to Liao et al.⁸ Clearly one of the challenges to the acceptance of bacterial agents as the cause of these autoimmune diseases has been that there is no universally observed association or one specific universally causative agent. This issue is addressed head on in research by Harkiolaki et al. using a mouse model of multiple sclerosis (MS), when they state:

We show that a microbial peptide, common to several major classes of bacteria, can induce MS-like disease in humanized mice by cross-reacting with a T cell receptor (TCR) that also recognizes a peptide from myelin basic protein, a candidate MS auto-antigen. Structural analysis demonstrates this cross-reactivity is due to structural mimicry of a binding hotspot shared by self and microbial antigens, rather than to a degenerate TCR recognition. Thus, these data suggest a possible explanation for the difficulty in incriminating individual infections in the development of MS.⁹

This phenomenon is also likely in play across a multitude of autoimmune disorders, and not something unique to MS.

Researchers have now gone beyond establishing mere associations between the presence of various microbes and autoimmune disorders. Some have actually experimentally induced autoimmune disease by infecting animals with specific pathogens. Mazmanian et al. inoculated a wild-type mouse with the bacterium Helicobacter hepaticus to create an experimental mouse version of the autoimmune disorder inflammatory bowel disease (IBD).¹⁰ H. hepaticus activates Th17 cells, which release cytokines associated with inflammation, such as IL-17, which cause symptoms of the disease. They then introduced Bacteroides fragilis, expressing the polysaccharide A (PSA) to the gut of the animals, where the PSA molecule was taken up by dendritic cells and presented on their surface, activating CD4 T cells and regulatory T cells (Tregs). The Tregs release IL-10, which suppresses the inflammatory action of IL-17, alleviating the IBD in mice. In summary, the researchers induced autoimmune disease by introducing specific bacteria to the gut, and resolved it by introducing another, making a compelling argument for a causal relationship between the GI microbiota and autoimmune activity.

Autoimmune thyroid disorders also have been linked to bacterial infections, mainly GI overgrowth of the opportunistic organism Yersinia enterocolitica. Petru et al. state: Yersinia shows on its surface saturable binding sites for TSH. TSH receptor antibodies could be produced in selected individuals having been infected with bacteria showing TSH receptors. It may, therefore, be assumed that the gram-negative bacterium Yersinia enterocolitica may have an active part in triggering immunogenic thyroid diseases.¹¹

Other researchers have shown a much higher prevalence of Yesinia serum antibodies in patients with thyroid disease versus controls. However, once again, there is no universal causality established, as autoimmune phenomena are a complex issue and seems to be potentially fueled by a multitude of potential antecedents, triggers, and mediators. For example, dietary antigens have also been linked to autoimmune thyroid disease. Celiac patients have approximately 10 times the rate of autoimmune thyroid diseases (such as Hashimoto's thyroiditis and Graves' disease) as nonceliac individuals, reflective of the affinity of gluten-gliadin antigen-antibody complexes for thyroid tissue.¹² It may be no coincidence that the emergence of an apparent epidemic of autoimmune diseases has corresponded with the ever-increasing consumption of poor-quality modern processed foods known to both negatively alter the GI microbiome and to contain a constant (often hidden) stream of offending dietary antigens, including gluten-containing grains.

While all of these associations may be interesting to researchers, what does this really mean to a clinician? Some critics would argue that there is a lack of interventional data to suggest that eradication of these associated organisms and/or avoidance of these dietary antigens positively affects patient outcomes. This may be true in some instances, but it has been well established, for instance by Ebringer, that successful treatment of Proteus clinically helps those with RA, and dietary elimination of gluten-containing grains is entirely accepted as the most viable intervention in celiac disease.⁷ One potential issue in play is that by the time a patient is diagnosed with autoimmune disease, there is often already substantial host-tissue damage. Perhaps the horse has already left the barn? However, what if potential triggers were routinely screened for and removed by health-care providers, particularly in those with a family history of autoimmune disorders? The entire course of the

disorder might be favorably altered, and many of these disorders might potentially never emerge clinically.

In the naturopathic and functional medicine models, there is a strong emphasis on both early detection and interventions that target the underlying pathophysiologic basis and underlying dysfunction of a disease process. Therefore, in these models the goal is to take clinical actions to reduce the potential for the disease process to progress. This also seems to intuitively make sense even in those who already have established disease; even though you may not be able to undo the damage already done, you can likely – if nothing else – slow down the train. This is particularly true since the interventions required pose little or no risk and are also relatively inexpensive, including probiotics, antimicrobial botanicals and volatile oils, mucosal-supporting nutrients and botanicals, and dietary modulation. Substantially improved molecular methods to assess the GI microbiota, utilizing PCR-DNA analysis, are also now available to clinicians at relatively low cost with rapid turnaround time.¹³

The Hygiene Hypothesis

The concept of the hygiene hypothesis is also quite simple, with the complexity being in the details. The thought that we have induced dysregulation into our immune systems by virtue of living in too clean an environment and the overeradication of infection is not new (see Figure 1), but it has gained favor with researchers who have begun to work out exactly why this may be the case. Some of these concepts were elegantly addressed by Weiss in an editorial in the New England Journal of Medicine, "Eat Dirt – The Hygiene Hypothesis and Allergic Disease."¹⁴ While there is no doubt that modern public health measures, such as adequate sewage systems, water treatment, the use of antibiotic agents, and various other aspects of modern hygiene have lessened deadly infectious outbreaks

and prevented unnecessary deaths, as with most things, there is a yin and yang. This "clean new world" has likely resulted in a lack of adequate sampling of our environment, including exposure to all of the microbes that we share our planet with, particularly while we are young and our immune systems are developing the delicate balance between adequate defense and tolerance. In a 2010 paper in *Nature Reviews-Immunology* titled "Farm Living – Effects of Childhood Asthma and Allergy," authors Mutius and Vercelli state:

Numerous epidemiological studies have shown that children who grow up on traditional farms are protected from asthma, hay fever and allergic sensitization. Early-life contact with livestock and their fodder, and consumption of unprocessed cow's milk have been identified as the most protective exposures. Studies of the immunobiology of farm living point to activation and modulation of innate and adaptive immune responses by intense microbial exposures and possibly xenogenic signals delivered before or soon after birth.¹⁵

Does this mean that our children who are growing up in more urban and suburban environments, living in comparatively sterile homes, drinking chlorinated water, bathed and scrubbed daily with antibacterial soap, not allowed to play in the dirt, and given antibiotics every time they have a sniffle are actually being harmed from an immunologic perspective and will carry this dysfunction with them throughout their lives? This is likely the case, and one of the reasons why, as parents of two young boys, my wife and I constantly try and balance the need for cleanliness with allowing them to be children and dig in the dirt, play in the stream in our back yard, and otherwise sample their living environment.

The Role of Parasites

As reported by David Gutierrez in *NaturalNews*, researchers in a study conducted at the University

of Nottingham point out that humans and gastrointestinal parasites might have coevolved in a way that the parasites actually help regulate the human immune system to prevent allergies.¹⁶ They believe that over the course of millions of years, gastrointestinal parasites have evolved the ability to suppress the human immune system as a survival mechanism. Because parasitic infestation has been so common throughout human evolutionary history, the human immune system has in turn evolved to compensate for this effect. This means that if the parasites are removed, the immune system may actually function too strongly, resulting in maladaptive immune responses such as asthma, allergies, and eczema. To test this concept the researchers studied over 1500 children in rural villages in Vietnam where parasitic infestation with hookworm is extremely common and allergies are not. Eradication of parasitic infection resulted in skyrocketing incidence of allergy, including dust mite sensitivity, supporting the hypothesis that parasites were modeling their immune response.

With issues such as the hygiene hypothesis, and the role of parasites in immune function in mind, gastroenterologist and researcher Dr. Joel Weinstock, originally at the University of Iowa and now Tufts University, has performed novel work with subjects with inflammatory bowel disease (IBD).¹⁷ IBD was unheard of before the 20th century. Beginning of 20th-century incidence is thought to be about 1:10,000 and is now 1:250. Similar data exist with the incidences of asthma, hay fever, DM, MS, and so on. Weinstock conducted various studies of IBD patients and treated them with the therapeutic parasite *Trichuris suis*, a porcine whipworm, which was an ideal choice as it only remains viable in the human GI tract for a short time and must be continually administered. The organism, when introduced into patients with IBD induced changes in regulatory T cell function, blocked T cell proliferation, altered cytokine production and expression of innate immunity,

altered the intestinal flora, and generally produced a lessening of symptoms and severity of disease. Pharmaceutical agents are now being developed along these lines to treat IBD.

Intestinal Hyperpermeability (a.k.a. Leaky Gut Syndrome)

Leaky gut syndrome for much of the past 20 years seemed something that just functional medicine doctors talked about. Not any longer! Prestigious researchers such as Alessio Fasano at the University of Maryland have been researching the role of intestinal permeability in the pathogenesis of autoimmune disorders and bringing this concept full-speed to the conventional medical research community through his publications in top-tier immunology and gastroenterology journals.¹⁸ In a 2009 article in *Scientific American*, he eloquently brought the topic to the lay audience with his article "Surprises from Celiac Disease," where he described that his theory that leaky gut contributes to celiac disease and autoimmunity was initially greeted with skepticism by his colleagues.¹⁹ Fasano has proposed that for autoimmune disease to manifest, there must be three factors present, and he equates these to a triangle, or three-legged stool, where if any are not present the disease cannot exist. These three factors include: (1) an environmental trigger (i.e., antigen); (2) genetic susceptibility (i.e., an HLA pattern that is particularly efficient at presenting the antigen to the immune cells, such as the presence of the HLA-DQ2 and HLA-DQ2 pattern in celiac disease); and (3) intestinal hyperpermeability (i.e., "leaky gut syndrome"). He goes on to opine that by far the easiest of these three factors to alter clinically is intestinal permeability. Much of his work involves the study, and future therapeutic manipulation, of a protein which alters intestinal permeability by the name of zonulin.

Sapone et al., in a paper in *Diabetes* 2006, expand on the role of zonulin and leaky gut in autoimmune disorders, saying:

Zonulin, a protein that modulates intestinal permeability, is upregulated in several autoimmune diseases and is involved in the pathogenesis of autoimmune diabetes. Zonulin upregulation seems to precede the onset of the disease, providing a possible link between increased intestinal permeability, environmental exposure to non-self antigens, and the development of autoimmunity in genetically susceptible individuals.²⁰

Fasano best summarizes the role of intestinal mucosal health and hyperpermeability in autoimmunity in a 2005 paper when he states:

Together with the gut-associated lymphoid tissue and the neuroendocrine network, the intestinal epithelial barrier, with its intercellular tight junctions, controls the equilibrium between tolerance and immunity to nonself-antigens. When the finely tuned trafficking of macromolecules is dysregulated in genetically susceptible individuals, both intestinal and extraintestinal autoimmune disorders can occur.¹⁸

Functional medicine and naturopathic physicians, and other nutritionally minded providers have been addressing the issue of leaky gut for a long time with effective natural agents, including L-glutamine, N-acetyl-glucosamine, anti-inflammatory botanicals and bioflavonoids, mucilaginous herbs, zinc-carnosine, omega-3-fatty acids, and more. One popular nutrient that is used frequently as an immune modulator in autoimmune conditions is vitamin D. However, most clinicians are not aware of the role that vitamin D plays directly in intestinal permeability. According to Kong et al. in their 2008

paper "Novel Role of the Vitamin D Receptor in Maintaining the Integrity of the Gastrointestinal Barrier":

In vitro experiments demonstrate that the VDR mediates the activity of 1,25(OH)2D3 that induces junction protein expression and strengthens the tight junction complex. These data are consistent with, and explain at least in part, the observation reported in the literature that vitamin D deficiency is linked to increased incidence of IBD in human population.²¹

Another possible role for vitamin D in the treatment of autoimmune disease, including MS, involves antimicrobial action. In addition to the previously cited findings by Harkioliaki et al. regarding molecular mimicry induced by various GI bacteria in MS, researchers such as Dr. Charles Stratton at Vanderbilt University have made clear associations between MS and Chlamydia pneumoniae; and others, including Dr. Donald Gildea, have implicated various viral triggers in MS.^{9,22,23} It has also been shown that the human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly upregulated in myeloid cells by 1,25 dihydroxyvitamin D3.²⁴ Meaning that, as vitamin D levels rise, so does the production of this endogenous antimicrobial peptide in the body, and this may account for some of the clinical benefit observed with vitamin D therapy in MS and other autoimmune disorders.

Predictive Autoantibody Testing (A True Application of Preventive Medicine?)

In a 2007 Scientific American article titled "New Predictors of Disease," Abner Louis Notkins stated, "Molecules called predictive autoantibodies appear in blood years before people show symptoms of various disorders. Tests that detect these molecules could warn of the need to take preventive action."²⁵

While some of these tests have been used for many years in a very selective manner, often simply to confirm the presence of a disease strongly suspected by clinical presentation and examination, the development and availability of low-cost autoantibody arrays has ushered in the possibility to use autoantibody testing in a much more proactive screening strategy to predict the future emergence of autoimmune disorders so that preventive action can be initiated early to short-circuit the disease process.²⁶ Table 2 outlines some of the available predictive autoantibody tests, their positive predictive value (PPV), and the years before clinical diagnosis that they generally appear in the blood of subjects with specific disorders.²⁷⁻²⁹

According to Aristo Vojdani, PhD, autoantibodies could³⁰

- predict the risk of falling ill
- project the probability of contracting a particular disease so that the potential patient could consider preventive therapy
 - - as primary prevention to remove environmental factors that trigger disease
 - as secondary prevention, modulate the destructive process before onset of clinical symptoms
- anticipate the timing of a disorder, revealing how soon a disease is likely to cause symptoms
 - project the course of a disease
 - predict the severity and probable rate of progression of a disease
- classify the disease
 - in a patient with an established disease, autoantibodies can help define the nature of the condition as autoimmune or non-autoimmune

As inexpensive tests for predictive autoantibodies continue to be developed, they could become part of a routine check-up, particularly by preventive physicians such as naturopathic and functional medicine physicians.

Table 2: Selected Predictive Autoantibody Tests

Disease/Disorder	Autoantibody Tests	Years Prior to	
		Positive Predictive Value	Clinical Diagnosis
Addison's disease	*Adrenal cortex antibodies	70	10
Celiac disease	*Antitissue transglutaminase	50–60%	7
	*Antiendomysial antibodies	50–60%	
	*HLA-DQ2 or DQ8 antigens	100%	
Hashimoto's thyroiditis	*Antithyroid peroxidase antibodies (postpartum)	92%	7–10
Primary biliary cirrhosis	*Antimitochondrial antibodies	95%	26
Rheumatoid arthritis	*Rheumatoid factor	62–88%	14
	*Anticyclic citrullinated peptide	97%	
Scleroderma	*Anticentromere antibodies	100%	11
	*Antitopoisomerase I antibodies		
Sjögren's syndrome	*Anti-Ro and La antibodies	73%	5
SLE	*RNP, Sm, dsDNA, Ro, La, and cardiolipin antibodies	94–100%	7–10
Type 1 diabetes	*Pancreatic islet cell	43%	14
	*Insulin	55%	
	*65 kD glutamic acid decarboxylase	42%	
	*Tyrosine phosphatase-like protein	29%	

Summary

It is hoped that this article will help the physician to develop a comprehensive conceptual framework from which to view autoimmune disease and to institute a new proactive clinical model from which to evaluate patients. Physicians should look for immune dysregulatory conditions with a strong emphasis on very early detection with predictive autoantibodies, a focus on optimizing gastrointestinal mucosal immune function and the microbiome, the eradication of infectious triggers with antimicrobial therapy, the detection and elimination of food sensitivities, and the promotion of an anti-inflammatory lifestyle.



Dr. David M. Brady

is a Connecticut-licensed naturopathic medical physician, a doctor of chiropractic, and certified clinical nutritionist. He is the vice provost

of the Division of Health Sciences, director of the Human Nutrition Institute, and associate professor of clinical sciences at the University of Bridgeport. He is also the chief medical officer for Designs for Health Inc. and practices at Whole Body Medicine in Trumbull, Connecticut.

Notes

1. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. *N Engl J Med*. Sep 2002;347(12):911–920.
2. Inaba M, Ushijim S, Hirata N, et al. Methotrexate-related lymphomatoid granulomatosis in a patient with rheumatoid arthritis. *Nihon Kokyuki Gakkai Zasshi*. (Article in Japanese.) Aug 2011;49(8):597–601.
3. Mayes MD. Epidemiologic studies of environmental agents and systemic autoimmune diseases. *Environ Health Perspect*. 1999;107(suppl. 5):743–748.
4. Pishak OV. Bukovian State Medical Academy, Public Health Ministry of Ukraine. *Mikrobiol Z*. Sep–Oct 1999;61(5):41–47.
5. Tiwana H, Wilson C, Walmsley RS, et al. Antibody responses to gut bacteria in ankylosing spondylitis, rheumatoid arthritis, Crohn's disease and ulcerative colitis. *Rheumatol Int*. 1997;17:11–16.
6. Ebringer A, Rahid T. Rheumatoid arthritis is an autoimmune disease triggered by *Proteus* urinary tract infection. *Clin Dev Immunol*. Mar 2006;13(1):41–48.
7. Ebringer A, Rahid T, Wilson C. Rheumatoid arthritis: proposal for the use of anti-microbial therapy in early cases. *Scand J Rheumatol*. 2003;32:2–11.
8. Liao F, Li Z, Wang Y, et al. *Porphyromonas gingivalis* may play an important role in the pathogenesis of periodontitis-associated rheumatoid arthritis. *Med Hypotheses*. Feb 2009;72:732–735.
9. Harkiolaki M, Holmes SL, Svendsen P, et al. T-cell-mediated autoimmune disease due to low-affinity crossreactivity to common microbial peptides. *Immunity*. 20 Mar, 2009;30:348–357.
10. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. *Nature*. 29 May 2008;453(7195):620–625.
11. Petru G, Stunzner D, Lind P, et al. Antibodies to *Yersinia enterocolitica* in immunogenic thyroid diseases. *Acta Med Austriaca*. (Article in German.) 1987;14(1):11–14.
12. Anasaldi N, Palmas T, Corrias A, et al. Autoimmune thyroid disease and celiac disease in children. *J Pediatr Gastroenterol Nutr*. Jul 2003;37(1):63–66.
13. Brady D. Novel Options in GI diagnostics: DNA detection of gut microbiota. *Complementary Med*. Jul–Aug 2008:28–31.
14. Weiss ST. Eat dirt—the hygiene hypothesis and allergic disease (editorial). *N Engl J Med*. 19 Sep 2002;347(12):930–931.
15. von Mutius E, Vercelli D. Farm living: effects on childhood asthma and allergy. *Nat Rev Immunol*. Dec 2010;10(12):861–868.
16. Gutierrez D. Parasites in your gut actually help protect you from allergies [online article]. *NaturalNews*. http://www.naturalnews.com/028141_parasites_allergies.html. Accessed Nov 03, 2011.
17. Summers RW, Elliott DE, Weinstock JV, et al. *Trichuris suis* seems to be safe and possibly effective in the treatment of inflammatory bowel disease. *Am J Gastroenterol*. Sep 2003;98(9):2034–2041.
18. Fasano A, Shea-Donohue T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. *Nat Clin Pract Gastroenterol Hepatol*. Sept 2005;2(9):416–422.
19. Fasano A. Surprises from celiac disease. *Sci Am*. Aug 2009;301(2):54–61.
20. Sapone A, de Magistris L, Pietzak M. Zonulin upregulation is associated with increased gut permeability in subjects with type I diabetes and their relatives. *Diabetes*. May 2006;55(5):1443–1449.
21. Kong J, Zhang Z, Musch MW, et al. Novel role of the vitamin D receptor in maintaining the integrity

Brady David M. Autoimmune Disease. *Townsend Letter*. June 2012;347:45-50.

- of the intestinal mucosal barrier. *Am J Physiol Gastro Liver Physiol*. 2008;294:G208–G216.
22. Yao SY, Stratton CW, Mitchell WM. CSF oligoclonal bands in MS include antibodies against Chlamydoiphilia antigens. *Neurology*. 2001;56:1168–1176.
 23. Gildeen DH. Infectious causes of multiple sclerosis. *Lancet Neurol*. 2005;4:195–202.
 24. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D₃. *Future Microbiol*. 2009;4(9):1151–1165.
 25. Notkins AL. New predictors of disease. *Sci Am*. 2007;296(3):72–79.
 26. Leslie D, Lipsky P, Notkins AL. Autoantibodies as predictors of disease. *J Clin Invest*. 2001;108:1417–1422.
 27. O'Bryan T. American College for Advancement in Medicine annual symposium presentation 2009.
 28. Shoenfeld Y, Blank M, Abu-Shakra M, et al. The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune disease. *IMAJ*. 2008;10:13–19.
 29. Lindberg B, Iverson SA, et al. Islet autoantibodies in cord blood in children who develop Type I (insulin-dependent) diabetes mellitus before 15 years of age. *Diabeteologia*. 1999;42:181–187.
 30. Vojdani A. Antibodies as predictors of complex autoimmune diseases and cancer. *Int J Immunopathol Pharmacol*. Jul–Sep 2008;21(3):553–566.
-